Tag Archives: Alan Carr

Needham Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)

Needham analyst Alan Carr reiterated a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) yesterday and set a price target of $62. The company’s shares closed yesterday at $50.72. According to TipRanks.com, Carr is a 3-star analyst with

Needham Sticks to Their Hold Rating for Neurocrine (NBIX)

Needham analyst Alan Carr maintained a Hold rating on Neurocrine (NBIX – Research Report) yesterday. The company’s shares closed yesterday at $95.95. According to TipRanks.com, Carr is a 3-star analyst with an average return of 2.3% and a 41.0% success

Needham Sticks to Their Buy Rating for ACADIA Pharmaceuticals Inc (ACAD)

Needham analyst Alan Carr maintained a Buy rating on ACADIA Pharmaceuticals Inc (ACAD – Research Report) on June 27 and set a price target of $40. The company’s shares opened today at $26.99, close to its 52-week high of $28.67.

Needham Sticks to Their Buy Rating for SCYNEXIS (SCYX)

In a report issued on May 10, Alan Carr from Needham maintained a Buy rating on SCYNEXIS (SCYX – Research Report), with a price target of $5. The company’s shares closed on Friday at $1.49. Carr said: “Scynexis reported 1Q19

Needham Maintains a Hold Rating on Tetraphase (TTPH)

In a report issued on May 10, Alan Carr from Needham maintained a Hold rating on Tetraphase (TTPH – Research Report). The company’s shares closed on Friday at $0.98, close to its 52-week low of $0.95. Carr commented: “Tetraphase reported

Gilead Sciences (GILD) Gets a Hold Rating from Needham

In a report issued on May 3, Alan Carr from Needham maintained a Hold rating on Gilead Sciences (GILD – Research Report). The company’s shares closed on Friday at $67.13. Carr observed: “Gilead reported $5.28B in 1Q19 total revenue, in